Login or sign up
For business

Celcuity

4.2Β· 13 reviews
Average ratingGreat
4.2/ 5

Based on 13 reviews

538%
438%
323%
20%
10%
Ask AI

Questions about Celcuity

Based on 13 reviews, listing data and website checks Β· updated 7 days ago

What is Celcuity?

Celcuity is a commercial-stage biotechnology company based in Minneapolis, MN, that develops and commercializes targeted therapies for breast cancer and other solid tumors. Their lead candidate is gedatolisib, a dual PI3K - mTOR inhibitor known as REVTORPYKβ„’. They focus on the PAM (PI3K/AKT/mTOR) pathway to disrupt oncogenic processes in cancer patients.

Where is Celcuity located and how can it be contacted?

The company is located at 16305 36th avenue north in Minneapolis, MN, and can be reached by phone at 7637109862. They operate in the biotechnology industry and serve patients with solid tumor indications including breast cancer.

How recent are the customer reviews?

The most recent reviews on Trustburn were posted in November 2023, with the latest entry dated November 15, 2023. All thirteen reviews were submitted between January 2022 and November 2023.

What do reviewers praise about Celcuity?

Reviewers frequently praise Celcuity for providing top-notch services, exceptional customer support, and high-quality products. Many customers also highlight the friendliness of the staff and their willingness to go above and beyond to ensure satisfaction.

What specific features or services are highlighted in the reviews?

Some reviewers mention that the website provides in-depth information about their innovative approach to cancer treatment, which helps build confidence in their medical guidance options.

What recent news or regulatory updates are associated with Celcuity?

News articles confirm that Celcuity announced FDA acceptance of sNDA for REVTORPYKβ„’ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer. The FDA assigned a PDUFA goal date of June 25, 2027 for this approval.

What specific terms or trademarks are used on Celcuity's website?

The company's website mentions the REVTORPYKβ„’ trademark and highlights their focus on the PAM pathway. They also describe themselves as advancing next-generation therapies for breast cancer and other solid tumors.

Who is the target audience for Celcuity's therapies?

The company targets patients with specific cancer types, particularly those involving the PAM pathway. Their lead candidate, gedatolisib, is designed to inhibit the target pathway to disrupt the oncogenic process.

Which markets or countries does Celcuity serve?

The company appears to serve the United States market, as indicated by their Minneapolis address and FDA-related news. They also engage with investors through conferences like the Stifel 2026 Healthcare Conference.

How is Celcuity rated on Trustburn?

On Trustburn, Celcuity has a rating of 4.2 out of 5 based on 13 reviews.

Is Celcuity on social media?

Celcuity has official profiles on Linkedin.

AI-generated from reviews on this page. Verify anything important with the company directly.

Natalie Hanna-Pletz
Reviews 1

I recently discovered the company while researching personalized medicine options. The in-depth information provided on their website was truly impressive, and it gave me a clear understanding of their innovative approach to cancer treatment. The focus on identifying specific cell signals for targeted therapies is revolutionary. This level of transparency and expertise gave me confidence in considering them for medical guidance. The website's layout and user-friendly interface made navigation a breeze. The resources available to visitors, such as detailed case studies and clinical trial information, showcased the company's dedication to advancing cancer care. Overall, my experience with the company's website was very positive and I'm grateful for the valuable insights it provided.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website β€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Celcuity

Targeted therapies only work when inhibiting the target pathway disrupts the oncogenic process. Celcuity’s platform provides unparalleled insights into oncogenic pathways. We harness these insights to develop new targeted therapies for cancer patients. Our lead candidate is gedatolisib, a dual PI3K - mTOR inhibitor.

Celcuity: Revolutionizing Cancer Treatment with Unparalleled Insights into Oncogenic Pathways

Cancer is one of the most devastating diseases that affect millions of people worldwide. Despite significant advancements in cancer research, treatment options remain limited and often ineffective. Targeted therapies have emerged as a promising approach to treating cancer by inhibiting specific pathways that drive tumor growth and progression. However, these therapies only work when inhibiting the target pathway disrupts the oncogenic process.

This is where Celcuity comes in. Celcuity is a biotechnology company that specializes in developing targeted therapies for cancer patients by providing unparalleled insights into oncogenic pathways. The company's platform uses proprietary CELx technology to analyze patient-derived cells and identify aberrant signaling pathways that drive tumor growth.

By analyzing patient-derived cells, Celcuity can identify unique biomarkers and signaling pathways that are specific to each patient's cancer type. This allows the company to develop personalized treatments tailored to each patient's individual needs, increasing the chances of success while minimizing side effects.

Celcuity's lead candidate is gedatolisib, a dual PI3K-mTOR inhibitor designed to target multiple oncogenic pathways simultaneously. This drug has shown promising results in preclinical studies and is currently undergoing clinical trials for breast cancer patients with PIK3CA/AKT1/PTEN-altered tumors.

In addition to gedatolisib, Celcuity has several other drug candidates in its pipeline targeting various types of cancers such as lung, ovarian, pancreatic cancers among others.

What sets Celcuity apart from other biotech companies working on targeted therapies is its unique approach towards identifying novel targets for therapy development using its proprietary CELx technology platform which provides unparalleled insights into oncogenic pathways.

The CELx technology platform enables researchers at Celcuity to analyze live human tumor cells obtained directly from patients without any genetic modification or manipulation required before testing them against different drugs or combinations thereof under controlled conditions mimicking those found within human tumors themselves - something no other company can do today!

Moreover, this approach allows researchers at Celcuity not only identify new targets but also validate existing ones more accurately than ever before - leading ultimately towards better outcomes for patients suffering from various forms of cancers worldwide!

In conclusion, Celcuity represents an exciting new frontier in personalized medicine by harnessing unparalleled insights into oncogenic pathways through its proprietary CELx technology platform which enables researchers at this innovative biotech firm not only identify novel targets but also validate existing ones more accurately than ever before! With their lead candidate gedatolisib showing promising results already underway clinical trials breast cancer patients PIK3CA/AKT1/PTEN-altered tumors among others; it seems clear why investors should keep an eye out on this emerging player within healthcare space!

Address
16305 36th avenue north
Categories
Biotechnology